Cefaclor - instructions for use, dose, side effects, contraindications

Clinical and pharmacological group: & nbsp

Cephalosporins

Included in the formulation

Cefaclor Stade®

granulescapsulessuspension inwards

SHTADA Artznajmittel AG Germany

Cefaclor Stade®

granulescapsules inwards

SHTADA Artznajmittel AG Germany

АТХ:

J.01.D.C.04 Cefaclor

Pharmacodynamics:

Cephalosporin antibiotic II generation for oral administration.

Has bactericidal action due to inhibition of bacterial cell wall synthesis. Violates the synthesis of the biopolymer peptidoglikana - the main component of the cell wall of bacteria. It inhibits the peptidoglycan transpeptidase, inhibits the activity of the endogenous inhibitor, which leads to activation of murein hydrolase, which cleaves peptidoglycan. Effective against fissile bacteria, in the walls of which the synthesis of peptidoglycan occurs.

Highly active against gram-negative bacteria: Escherichia coli, Haemophilus influenzae, Salmonella spp., Shigella spp., Proteus mirabilis, Klebsiella spp., Neisseria gonorrhoeae; Gram-positive bacteria: Staphylococcus spp., Streptococcus spp.; anaerobic bacteria: Bacteroides spp., Peptostreptococcus spp.

Inactive for Pseudomonas spp., most strains Enterococcus spp., many strains Enterobacter cloacae, methicillin-resistant strains Staphylococcus spp. and Listeria monocytogenes.

Resistant to the action of β-lactamases.

Pharmacokinetics:

After ingestion with food up to 98% is absorbed in the gastrointestinal tract.The maximum concentration in the blood plasma is reached after 0.5-1 h. The connection with plasma proteins is 25%.

It is not metabolized. Does not penetrate the blood-brain barrier.

The elimination half-life is 0.6-0.9 hours. Elimination by the kidneys is unchanged.

Indications:

It is used for treatment of infectious and inflammatory diseases caused by sensitive to cefaclor pathogenic microflora: the diseases of the upper and lower respiratory tract, urinary tract, skin and soft tissues, otitis media with an average, sinusitis, osteomyelitis, gonorrhea, endometritis.

ICD-10

I.A50-A64.A54 Gonococcal infection

VIII.H60-H62.H60.9 External otitis, unspecified

VIII.H65-H75.H66 Purulent and unspecified otitis media

X.J30-J39.J32.9 Chronic sinusitis, unspecified

X.J00-J06.J01.9 Acute sinusitis, unspecified

X.J00-J06.J02.9 Acute pharyngitis, unspecified

I.A50-A64.A54.5 Gonococcal pharyngitis

X.J30-J39.J31.2 Chronic pharyngitis

X.J00-J06.J03.9 Acute tonsillitis, unspecified

X.J30-J39.J35.0 Chronic tonsillitis

X.J00-J06.J06 Acute upper respiratory tract infections of multiple and unspecified sites

X.J20-J22.J22 Acute respiratory infection of lower respiratory tract, unspecified

XII.L00-L08 Infections of the skin and subcutaneous tissue

XIV.N10-N16.N12 Tubulointerstitial nephritis, not specified as acute or chronic

XIV.N10-N16.N11 Chronic tubulointerstitial nephritis

XIV.N10-N16.N10 Acute tubulointerstitial nephritis

XIV.N30-N39.N39.0 Urinary tract infection without established localization

XIV.N70-N77.N71.9 Inflammatory disease of uterus, unspecified

Contraindications:Individual intolerance of β-lactam antibiotics: penicillins and cephalosporins, children's age up to 1 month.

Carefully:

Imbalance of electrolytes or fluid, a history of bronchial asthma, severe liver damage, malabsorption syndrome.

Pregnancy and lactation:

Recommendations for FDA - Category B. It is used in pregnancy and lactation.

Dosing and Administration:

Use in children

Contraindicated in children under the age of 1 month.

Inside, the maximum daily dose of 40 mg / kg.

Adults

Inside, 250-500 mg 3 times a day.

The highest daily dose: 4 g.

The highest single dose: 500 mg.

Side effects:

Central and peripheral nervous system: headache, dizziness.

Hemopoietic system: leukopenia, thrombocytopenia, hemolytic anemia, eosinophilia, hypoprothrombinemia.

Digestive system: nausea, vomiting, diarrhea, cholestatic jaundice, pseudomembranous colitis, increased activity of hepatic transaminases, hepatitis.

Dermatological reactions: hyperhidrosis, rash, itching, candidiasis.

Urinary system: interstitial nephritis.

Allergic reactions.

Overdose:

Increased side effects.

Treatment is symptomatic.

Interaction:

When used simultaneously with aminoglycosides, butadione, polymyxins, the risk of nephrotoxicity increases.

Increase the effect of aminoglycosides, metronidazole, polymyxins, rifampicin, weaken - levomitsetin, tetracyclines.

Kolestyramin reduces the absorption of cefaclor.

Special instructions:

Control of prothrombin time and bleeding time.

During treatment, a false positive Coombs reaction and a false positive urine reaction to glucose are possible.

Instructions

Cefaclor (Cefaclorum)